Stocks pulled back from yesterday's records and oil prices settled around $100 a barrel with traders awaiting signs that the Middle East war is winding down. Brent crude futures pared an early slide ...

The State Street SPDR S&P 500 ETF Trust (SPY +0.45%) is one of the largest exchange-traded funds (ETFs) on the planet today. The investment vehicle tracks the S&P 500 index, which itself tracks the ...

Here are the top stories to read during Tuesday's trading: ...

Stock Market News, May 7, 2026: Dow falls 314 points, S&P 500 and Nasdaq finish the day lower after hitting intraday records; investors watch oil prices in hopes of end to Iran war The U.S.

The Nasdaq pulled back from yesterday’s record close because a new headline had Wall Street worried about AI just one day before some of the biggest spenders are set to share quarterly results. The ...

The S&P 500 and Nasdaq locked in their best month since 2020 with a record closing high on Thursday despite struggles from three of the biggest U.S. firms. The Nasdaq rose 0.9%. The S&P 500 rose ...

Entrada Therapeutics’ Duchenne muscular dystrophy (DMD) data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout from a key readout expected to ...

Investors kicked off May on an optimistic note, sending the S&P 500 and Nasdaq to fresh records. Oil prices fell and stocks extended gains after reports Friday morning that Iran had shared its latest ...

Gary Shilling thinks there's almost nothing that can stop a US recession this year. The legendary economist and Merrill Lynch alum laid out a grim outlook for markets and the economy in an interview ...

Ed Yardeni, Yardeni Research president, joins 'Closing Bell' to discuss Yardeni's thoughts on equity markets, market valuations and much more. Got a confidential news tip? We want to hear from you.

Earlier in the year, inflation was trending lower and jobs growth had flatlined, so investors expected the Federal Reserve to cut interest rates at least twice in 2026. Specifically, futures traders ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...